Nurix Therapeutics Inc At Bexobrutideg Investor Update Transcript - Thomson StreetEvents

Nurix Therapeutics Inc At Bexobrutideg Investor Update Transcript

Nurix Therapeutics Inc At Bexobrutideg Investor Update Transcript - Thomson StreetEvents
Nurix Therapeutics Inc At Bexobrutideg Investor Update Transcript
Published Oct 22, 2025
25 pages (13398 words) — Published Oct 22, 2025
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of NRIX.OQ corporate analyst meeting

  
Brief Excerpt:

...Good morning and welcome to the Nurix Therapeutics conference call. I'm Arthur Sands, President and CEO, and I'm joined today on this call by Gwenn Hansen, our Chief Scientific Officer, Paula O'Connor, our Chief Medical Officer, and Hans van Houte, our Chief Financial Officer. These are our disclaimers. At Nurix, we're advancing a pipeline of innovative targeted protein degrader drugs in oncology and inflammation and immunology or I&I, each with best-in-class potential. The majority of today's call will be focused on an important update on our lead program in CLO Bexobrutideg, or NX-59488, or Bexdeg for short. This will include our pivotal clinical development plans and some important new data supporting differentiation and Bexdeg dose selection for registrational trials. Next, with respect to our partnered I&I pipeline, we are able to share with you today some new preclinical data from both STAT6 and the IRAK4 programs. Our STAT6 program is partnered with Sanofi, and this is the first...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Nurix Therapeutics Inc
Ticker
NRIX.OQ
Time
12:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Roger Song - Jefferies - Analyst : Can you hear me?

Question: Roger Song - Jefferies - Analyst : I can hear you. Awesome. Yeah. Thank you for calling me. Congrats for the start of the pivotal and then sharing with us a lot of the new data today. Thank you. So, my question is related to, the detail of the pivotal study design. Given your, the phase two is a Single-Arm. So, what is the stat assumption for the 100 patient, for this, post-COVID and non-COVID and DCLA too, and a similar question for the second plus line randomized confirmatory study, you have a dealer's choice, multiple compared the arms, so what, how should we think about the statistical assumption on the primary endpoint, and then maybe more specific, any, the caps for all of those compared to arm you will be enrolling in order to power the study. Thank you.

Table Of Contents

Nurix Therapeutics Inc to Discuss Data Presented at ASH Transcript – 2025-12-09 – US$ 54.00 – Edited Transcript of NRIX.OQ conference call or presentation 9-Dec-25 1:15am GMT

Nurix Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript – 2025-09-10 – US$ 54.00 – Edited Transcript of NRIX.OQ presentation 10-Sep-25 11:00am GMT

Nurix Therapeutics Inc To Discuss Data From The Ongoing Phase 1 Clinical Trial Transcript – 2025-06-12 – US$ 54.00 – Edited Transcript of NRIX.OQ conference call or presentation 12-Jun-25 12:00pm GMT

Nurix Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript – 2025-05-21 – US$ 54.00 – Edited Transcript of NRIX.OQ presentation 21-May-25 6:05pm GMT

Nurix Therapeutics Inc Annual Shareholders Meeting Transcript – 2025-05-19 – US$ 54.00 – Edited Transcript of NRIX.OQ shareholder or annual meeting 19-May-25 4:00pm GMT

Nurix Therapeutics Inc at Barclays Global Healthcare Conference Transcript – 2025-03-12 – US$ 54.00 – Edited Transcript of NRIX.OQ presentation 12-Mar-25 2:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Nurix Therapeutics Inc At Bexobrutideg Investor Update Transcript" Oct 22, 2025. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Nurix-Therapeutics-Inc-At-Bexobrutideg-Investor-Update-T16538971>
  
APA:
Thomson StreetEvents. (2025). Nurix Therapeutics Inc At Bexobrutideg Investor Update Transcript Oct 22, 2025. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Nurix-Therapeutics-Inc-At-Bexobrutideg-Investor-Update-T16538971>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.